These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18654595)

  • 21. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models.
    Moestue SA; Borgan E; Huuse EM; Lindholm EM; Sitter B; Børresen-Dale AL; Engebraaten O; Maelandsmo GM; Gribbestad IS
    BMC Cancer; 2010 Aug; 10():433. PubMed ID: 20716336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
    Alimonti A; Ferretti G; Cognetti F
    J Clin Oncol; 2005 Dec; 23(34):8918; author reply 8918-9. PubMed ID: 16314657
    [No Abstract]   [Full Text] [Related]  

  • 24. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
    Yu KD; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
    [No Abstract]   [Full Text] [Related]  

  • 25. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes.
    Tot T
    Clin Breast Cancer; 2011 Aug; 11(4):258-63. PubMed ID: 21729662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O; Wang SA; Hileeto D
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
    Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
    Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of biphasic metaplastic sarcomatoid carcinoma of the breast by evaluation of immunohistochemical markers.
    Chien T; Chou J; Chang T; Lin C
    Hematol Oncol Stem Cell Ther; 2010; 3(2):89-93. PubMed ID: 20543543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metaplastic breast carcinoma: pathology and clinical outcome.
    Bellino R; Arisio R; D'Addato F; Attini R; Durando A; Danese S; Bertone E; Grio R; Massobrio M
    Anticancer Res; 2003; 23(1B):669-73. PubMed ID: 12680165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diverse histomorphology of HER2-positive breast carcinomas based on differential ER expression.
    Akashi M; Yamaguchi R; Kusano H; Obara H; Yamaguchi M; Toh U; Akiba J; Kakuma T; Tanaka M; Akagi Y; Yano H
    Histopathology; 2020 Mar; 76(4):560-571. PubMed ID: 31554015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
    East EG; Pang JC; Kidwell KM; Jorns JM
    Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
    Popovska S; Ivanov I
    Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p16INK4a expression in basal-like breast carcinoma.
    Bohn OL; Fuertes-Camilo M; Navarro L; Saldivar J; Sanchez-Sosa S
    Int J Clin Exp Pathol; 2010 Jun; 3(6):600-7. PubMed ID: 20661408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.
    Keshgegian AA
    Breast Cancer Res Treat; 1995 Aug; 35(2):201-10. PubMed ID: 7647342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.